Bajaj Healthcare Ltd.
Snapshot View

903.00 -10.55 ▼-1.2%

27 July 2021, 10:55:00 A.M.
Volume: 9,848

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bajajhealth.com
Financial Indicators
Market Cap 1,260.63 Cr.
Earnings per share (EPS) 60.23 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 15.17 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 187.15 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.88 Calculated using Price: 913.55
Dividend Yield 0.30 Period Ending 2020-03
No. of Shares Subscribed 1.38 Cr. 13,799,200 Shares
FaceValue 10
Company Profile

The company was incorporated as Bajaj Healthcare Private Limited on July 15, 1993 under the Companies Act, 1956, with the Registrar of Companies, Mumbai bearing Registration Number - 072892. The status of the company was changed to a public limited company and the name of the company was changed to Bajaj Healthcare Limited by a special resolution passed on March 15, 2005. A fresh certificate of incorporation consequent to the change of name was granted to the company on March 31, 2005, by the Registrar of Companies, Mumbai. The company began its operations in the year 1993 with an API manufacturing unit in Tarapur, near Mumbai. Over the years it has expanded its scale and scope of operations and currently it operates five manufacturing units for manufacture of APIs, Intermediates and Formulations.

The company’s present product portfolio consists of various APIs in the therapeutic categories of Neutraceutical (Amino Acids), Vitamins, Anti-Convulsants, Bactericidal & Bacteriostatic, Diuretic & Vasodilator, Mineral & Nutritional supplements, Bronchodilater / Anti-asthmatic and Nootropics. The company’s Formulations unit manufactures tablets, capsules and sachets for its own brands as well as under Loan License (job work) for other pharmaceutical companies. Currently, the company manufactures formulations for GlaxoSmithKline Pharmaceuticals (GSK) and USV (USV) on a Loan License basis. The formulations manufactured for its own brands are manufactured and marketed under a separate division of Bajaj Medicare and it also has marketing tie-up with TTK Healthcare. The FDFs manufactured by it covers various therapeutic segments like Antibiotics, Anti-Arrhythmia, Anti-Convulsants, Anti-Diabetes, Anti-Platelets, NSAIDs, Vitamins & its Derivatives, Anti-Hypertensive, Anti-Bacterial, Anti-Malarial, Cholinesterase Inhibitors, etc.

With the combined production of its API facilities and that of its Formulation unit, the company’s product portfolio consists of APIs and FDFs which shall be marketed in domestic and international markets as branded generics. Presently it is supplying its APIs and FDFs both domestically and exporting to various countries in regions like, Europe, USA, Australia, Africa, South America, etc. With its long standing operations and quality products, the company has built a strong relationship with its customers for both APIs and FDFs. Some of its major clients include nationally and internationally known pharmaceutical companies like Glaxo Smithkline Consumer Healthcare, Ava Inc., Abbott Healthcare, Piramal Enterprises, Pfizer, Colgate Palmolive India, Lupin and Intas Pharmaceuticals to name a few.

Business area of the company

Bajaj Healthcare is a pharmaceutical company with manufacturing and marketing capabilities in Active Pharmaceutical Ingredients (APIs), Intermediates and Finished Dosage Formulations (FDFs) with focus on Vitamins, Amino Acids, Anti-Convulsants and Finished Dosage Forms (FDFs) caters to various therapeutic segments.

Major events

  • 1993-1994: Incorporated under Companies Act, 1956 as Bajaj Healthcare Private Limited by setting up plant at Tarapur.
  • 1996-1997: First Export Sale.
  • 2004-2005: Changed the status of the company from Private to Public i.e. to Bajaj Healthcare Limited.
  • 2005-2006: Purchase and Set-up a new facility at Salvi, Vadodara.
  • 2005-2006: Set up Corporate Office in Masjid Bunder.
  • 2006-2007: Purchase addition Plot N- 128 at Tarapur.
  • 2006-2007: Issued 20,00,000, Non- Cumulative Preference Shares of Rs 10 each.
  • 2006-2007: Major Term loan of Rs 863.00 lakhs was sanction and its total indebtedness reached to Rs 2,265 Lakh.
  • 2007-2008 Purchase and Set-up a new facility at Manjusar, Vadodara.
  • 2007-2008 Increase in Capacity of its major products like; 100% Vitamin C and its derivatives and 50% in Choline Bitartrate, etc.
  • 2009-2010: Launched own brands under Manjusar/ Medicare.
  • 2013-2014: Purchase and Set-up a new facility at Panoli, Ankleshwar.
  • 2013-2014: First GVK Agreement.
  • 2013-2014: First USV Agreement.
  • 2014-2015: Purchase and Set-up a Second facility at Tarapur, Maharashtra.
  • 2015-2016: Acquisition of premises for new Corporate Office in Thane and set-up of the same.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.15%
1 Week
+1.14%
1 Month
+28.18%
3 Month
+84.34%
6 Month
+91.11%
1 Year
+164.11%
2 Year
+403.34%
5 Year
+920.57%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.24 -3.74 7.31 22.38 19.60 10.77 17.68 20.18 22.40
Return on Capital Employed (%) 7.09 5.11 10.67 19.16 18.00 14.52 18.25 19.75 20.98
Return on Assets (%) 0.31 -0.84 1.53 4.50 4.12 3.65 6.23 6.10 7.59

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 30 29 31 82 89 99 114 129 152
Non Curr. Liab. 17 16 14 22 32 28 23 20 28
Curr. Liab. 74 85 99 85 88 93 131 117 146
Minority Int.
Equity & Liab. 121 130 145 189 209 219 268 267 326
Non Curr. Assets 59 59 59 110 131 128 129 130 145
Curr. Assets 62 71 86 79 78 91 140 137 181
Misc. Exp. not W/O
Total Assets 121 130 145 189 209 219 268 267 326

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 130 157 186 197 200 207 290 325 362
Other Income 0 0 0 0 0 2 2 1 3
Total Income 130 157 186 197 201 210 292 326 365
Total Expenditure -119 -144 -166 -168 -170 -176 -250 -282 -313
PBIDT 12 13 20 29 30 33 42 44 51
Interest -5 -6 -7 -8 -8 -8 -8 -8 -7
Depreciation -6 -8 -9 -9 -9 -11 -11 -11 -12
Taxation -1 0 -1 -5 -5 -6 -8 -8 -10
Exceptional Items
PAT 0 -1 2 8 8 8 15 16 23

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 9 15 17 28 25 22 17 25 21
Cash Fr. Inv. -15 -8 -9 -17 -31 -8 -12 -13 -28
Cash Fr. Finan. 6 -7 -8 -11 5 -13 2 -13 3
Net Change 0 0 1 0 0 0 7 0 -4
Cash & Cash Eqvt 1 0 1 1 0 1 8 8 4

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 67.26 67.26 67.26 67.26 67.26 67.26 67.26 67.26 67.26
Public 32.74 32.74 32.74 32.74 32.74 32.74 32.74 32.74 32.74
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 26 Jul 2021
Board Meeting Intimation for Considering And Approving Unaudited Financial Result For The Quarter Ended June 30 2021.
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2021 inter alia to consider and approve Pursuant to Regulation 29 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015 we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 03rd August 2021 inter alia to consider and approve:

-Unaudited Financial Result for the quarter ended June 30 2021.
-Any other matter with the permission of the Chair.

You are requested to take the same on record.
Wed, 21 Jul 2021
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015
In terms of regulation 30 of SEBI (LODR) Regulations 2015 please find attached herewith an update on units situated at Plot No.N- 216 & 217 and Plot No. N-128 MIDC Tarapur Boisar.

Kindly take the same on record.

Thanking you
Wed, 14 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 we enclose herewith certificate received from Link Intime India Private Limited The Registrar and Transfer Agent of the Company for the quarter ended 30th June 2021.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 696.90 -1.0%
Divi's Laboratories Ltd. 130,349.05 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,329.45 -1.5%
Cipla Ltd. 76,675.40 938.35 -1.3%
Cadila Healthcare Ltd. 61,992.73 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,086.80 -0.4%
Aurobindo Pharma Ltd. 55,837.02 948.70 -0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,329.45 -1.5%
Cipla Ltd. Consolidated 2021-03 31.88 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 948.70 -0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,329.45 -1.5%
Cipla Ltd. Consolidated 2021-03 4.18 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 948.70 -0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 0.18 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 948.70 -0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 10.09 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 948.70 -0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 12.53 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 948.70 -0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 17,131.99 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 948.70 -0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 1,546.98 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 948.70 -0.4%